The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Prolastin, Prolastin-C Market In 2026, And How Will Its Value Evolve By 2030?
Historically, the observed growth was propelled by the authorization for alpha-1 antitrypsin deficiency, its demonstrated effectiveness in safeguarding the lungs, its widespread acceptance among pulmonology specialists, the restricted number of alternative therapies, and the accessibility of plasma-derived proteins.
The anticipated market expansion throughout the forecast period is propelled by factors such as enhanced genetic screening rates, a heightened understanding of AAT deficiency, the proliferation of specialized care centers, an increasing burden of respiratory diseases, and improved adherence to long-term therapeutic regimens. Concurrently, significant developments expected during this timeframe involve the expanding utilization of alpha-1 replacement therapy, a greater availability of long-term lung protection treatments, an uptick in AAT deficiency diagnoses, the adoption of hospital-based augmentation therapy, and a concerted effort towards preventing the worsening of the disease.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19920&type=smp
Which Drivers Are Supporting The Prolastin, Prolastin-C Market Growth?
The prolastin, prolastin-C market is projected to expand due to the growing occurrence of respiratory infections. These infections target the respiratory system, encompassing the nose, throat, airways, and lungs, and originate from diverse pathogens like viruses, bacteria, fungi, or other microorganisms. An increase in such infections stems from factors including novel viral strains, seasonal variations, compromised immune systems, heightened environmental pollution, and greater human mobility. Prolastin and Prolastin-C, which are alpha-1 antitrypsin (AAT) replacement therapies, aid in addressing respiratory conditions, especially chronic obstructive pulmonary disease (COPD) linked to AAT deficiency. They achieve this by restoring the insufficient AAT protein, thereby decreasing lung inflammation, safeguarding against protease-induced tissue damage, and enhancing lung function and overall respiratory health for individuals with this genetic ailment. For example, the National Asthma Council, an Australia-based non-profit organization, reported in October 2024 that Australia registered 474 asthma-related deaths in 2023, consisting of 325 females and 149 males. This number closely mirrors the 473 asthma-related deaths documented in 2022, indicating a steady pattern in asthma mortality over these two years. Consequently, the rising incidence of respiratory infections is stimulating the growth of the prolastin, prolastin-C market.
How Is The Prolastin, Prolastin-C Market Categorized Across Its Segment Groups?
The prolastin, prolastin-c market covered in this report is segmented –
1) By Type: 20ml, 40ml
2) By Indication: Alpha-1 Antitrypsin Deficiency, Respiratory Health, Chronic Lung Disease, Genetic Disorders
3) By Application: Hospital, Pharmacy
Which Trends Are Influencing Demand In The Prolastin, Prolastin-C Market?
Major companies active in the peolastin and prolastin-C market are concentrating on clinical trials to evaluate the safety and effectiveness of pharmaceuticals. Clinical trials are investigative studies performed to assess the safety, efficacy, and potential side effects of novel treatments, drugs, or medical devices on human participants. For instance, in July 2023, Grifols SA, a Spain-based pharmaceutical company, announced that it had successfully enrolled 339 patients for the SPARTA (Study of ProlAstin-c Randomized Therapy with Alpha-1 Augmentation) phase 3 clinical trial. The purpose of this trial is to ascertain if patients with emphysema caused by alpha-1-antitrypsin (AAT) deficiency (alpha-1) experience a slower rate of lung tissue loss when receiving weekly treatment with two different dose regimens of Grifols Prolastin-C. This effort aims to evaluate Prolastin-C’s effectiveness in mitigating emphysema progression in alpha-1 antitrypsin deficiency (AATD) patients by elevating AAT protein levels through weekly administration of two active doses (60 and 120 mg/kg) when compared to a placebo.
Which Firms Are Influencing Competition In The Prolastin, Prolastin-C Market?
Major companies operating in the prolastin, prolastin-c market are Grifols SA
Get The Full Prolastin, Prolastin-C Market Report:
https://www.thebusinessresearchcompany.com/report/prolastin-prolastin-c-global-market-report
Where Is The Prolastin, Prolastin-C Market Most Concentrated Geographically?
North America was the largest region in the prolastin or prolastin-C market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prolastin, prolastin-c market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Prolastin, Prolastin-C Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/prolastin-prolastin-c-global-market-report
Browse Through More Reports Similar to the Global Prolastin, Prolastin-C Market 2026, By The Business Research Company
Proanthocyanidins Market Report 2026
https://www.thebusinessresearchcompany.com/report/proanthocyanidins-global-market-report
Isotretinoin Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/isotretinoin-drugs-global-market-report
Retinol Market Report 2026
https://www.thebusinessresearchcompany.com/report/retinol-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model